Dr Joe Renny, Head of Corporate Development, and Dr Simon Tyler, Chief Commercial Officer, CatSci, discuss the last 15 years of drug development, and what comes next. The American Cancer Society’s 2026 statistics tell a story that should be on the wall of every drug developer. Five-year survival for chronic… Read More
CatSci and Reach Industries have won an Innovate UK grant to accelerate the development of oligonucleotide therapeutics. The grant will fund a collaboration that combines scientific expertise with machine vision tools with an aim to streamline the synthesis, purification and analysis of RNA medicines. Read More
CatSci has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics. The acquisition was supported by Keensight Capital, private equity managers dedicated to pan-European Growth Buyout investments. Headquartered in the UK, and with laboratories in both the UK and… Read More
CatSci has won a Welsh Government SMART Capital Equipment Fund grant to enhance its oligonucleotides capability. The grant will enable the company to invest in new equipment that will increase the rapid creation of a large pool of candidates of RNA/DNA sequences. Production of… Read More
UK-based CatSci have expanded their offering to now include cGMP analytical capabilities for both small molecule and oligonucleotides. The new cGMP analytical capability will be led by Dr Sam Whitmarsh and Duncan Thompson, CatSci’s Director of Analytical Science and Digital Transformation, and Head of Dagenham site… Read More
